Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 2,101–2,200 of 4,108
Association of lower urinary tract symptoms and hip fracture in adults aged ≥ 50 years
Liu, P.-S., Huang, H., & Ding, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246653 · Cited by 7
Mohammed, L., & Dauod, A. S. (2021) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2021.008 · Cited by 7
Vertebral Fractures in Ireland: A Sub-analysis of the DXA HIP Project
Carey, J. J., Yang, L., Erjiang, E., Wang, T., Gorham, K., Egan, R., Brennan, A., Dempsey, M., Armstrong, C., Heaney, F., et al. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00868-7 · Cited by 7
Treatment indications and thresholds of intervention: consensus and controversies in osteoporosis
Chandran, M., & Kwee, A. K. (2021) · Climacteric · doi:10.1080/13697137.2021.1951205 · Cited by 9
Taylor, L. R., Kimata, C., Siu, A., Andrews, S. N., Purohit, P., Yamauchi, M., Bratincsák, A., Woo, R. K., Nakasone, C. K., & Lim, S. Y. (2021) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2021.08.002 · Cited by 8
Bone Health in Patients With Prostate Cancer: An Evidence-Based Algorithm
Johnson, E. D., Butler, K., & Gupta, S. V. (2021) · Federal Practitioner · doi:10.12788/fp.0155 · Cited by 7
Relationship between hinge fracture and postoperative axial symptoms after cervical laminoplasty
Xu, D., Zhou, C., Tao, H., et al. (2022) · British Journal of Neurosurgery · doi:10.1080/02688697.2021.1923647 · Cited by 7
“16 In addition to personal factors, surgical techniques are equally important.”
BackgroundA Machine Learning Approach for Predicting Therapeutic Adherence to Osteoporosis Treatment
Marvin, G., & Alam, M. G. R. (2021) · IEEE Asia-Pacific Conference on Computer Science and Data Engineering (CSDE) · doi:10.1109/csde53843.2021.9718416 · Cited by 8
Martín, M. B. C., Vega, L. L., Cabrera, J. A. B., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02129-5 · Cited by 7
Ketsiri, T., Uppuganti, S., Harkins, K. D., Gochberg, D. F., Nyman, J. S., & Does, M. D. (2022) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2022.2098016 · Cited by 9
“Bone fragility is a widespread problem and current X-ray based diagnostics have not proven effective in predicting who is likely to suffer a fragility fracture (Cosman et al. 2014; Kanis et al. 2001).”
BackgroundMahzari, M. M., Alibrahim, A. R., Alghamdi, N. A., Alsadhan, M. A., Almoamary, S. M., Masuadi, E., & Alshahrani, A. S. (2022) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_639_21 · Cited by 8
“Osteoporosis is the decrease in bone mineral density (BMD), which, in turn, leads to an increased risk of fractures.[1] Osteoporosis is a significant complication of chronic kidney disease (CKD), defined as a structural or functional kidney abnormality leading to decline in the glomerular filtration rate (≤60 mL/min).”
BackgroundCittadini, N., D’Angelo, D., Zannetti, E. B., Celi, M., Pennini, A., & Rocco, G. (2021) · International Journal of Bone Fragility · doi:10.57582/ijbf.210101.028 · Cited by 12
Miśkiewicz-Orczyk, K., Pluskiewicz, W., Kos‐Kudła, B., & Misiołek, M. (2023) · Medicina · doi:10.3390/medicina59050862 · Cited by 10
“Osteoporosis is a disease characterized by low bone mineral density and disorders of skeletal microarchitecture [16,17].”
BackgroundKim, E., Lee, H. W., Kim, S. S., Yoon, E. L., Jang, E. S., Chang, J., Cho, Y. Y., Seo, G. H., & Kim, H. J. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17716 · Cited by 9
“…that patients who received TAF experienced significantly smaller decreases in BMD than those who received TDF. Reducing BMD increases the risk of fracture exponentially 16 and whether the decline of BMD according to the drug actually leads to an increase in fractures needs to be confirmed.”
BackgroundRole of biophysical stimulation in multimodal management of vertebral compression fractures
Martino, A. C. D., Villari, E., Poluzzi, R., Brunello, M., Rossomando, V., D’Agostino, C., Ruta, F., & Faldini, C. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.11.023 · Cited by 8
“Current drugs include bisphosphonates, calcitonin, estrogen, selective estrogen receptor modulators, parathyroid hormone, and receptor activators of nuclear factor kappa-B ligand inhibitor [17].”
BackgroundThe ISCD and Vertebral Fractures
Vokes, T., & Lentle, B. C. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2014.11.004 · Cited by 8
Factors Associated with the Treatment of Osteoporosis in Korean Postmenopausal Women
Jeon, Y.-J., Kim, J. W., & Park, J.-S. (2013) · Women & Health · doi:10.1080/03630242.2013.862896 · Cited by 7
Osteoporosis: A Therapeutic Update
Mackey, P., & WHITAKER, M. D. (2015) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2015.08.010 · Cited by 7
Pharmacologic Management of Osteoporosis
Aynardi, M. C., & Ilyas, A. M. (2013) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2012.11.023 · Cited by 10
Medical Management of Fragility Fractures of the Distal Radius
Morgan, C. E. N., Crawford, M. D. A., Scully, M. W. F., & Noce, L. N. J. (2014) · Orthopedics · doi:10.3928/01477447-20141124-53 · Cited by 8
Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer
McKay, R. R., Taplin, M., & Choueiri, T. K. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.08.009 · Cited by 9
Nelson, S. D., Nelson, R. E., Cannon, G. W., Lawrence, P. T., Battistone, M. J., Grotzke, M. P., Rosenblum, Y., & Lafleur, J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2815-1 · Cited by 8
Denosumab for the Treatment of Postmenopausal Osteoporosis
Lewiecki, E. M. (2009) · Women s Health · doi:10.2217/17455057.5.1.15 · Cited by 7
Self-citationOsteoporosis among older Saudis: risk of fractures and unmet needs
Amin, T. T., Owaifeer, A. M. A., Al-Hashim, H., et al. (2013) · Archives of Osteoporosis · doi:10.1007/s11657-013-0118-3 · Cited by 7
Osteoporosis management: translating research into optimal fracture protection II
Singer, A. J., & Boonen, S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802115887 · Cited by 7
Adult bone strength of children from single-parent families: the Midlife in the United States Study
Crandall, C. J., Karlamangla, A. S., Merkin, S. S., Binkley, N., Carr, D., Greendale, G. A., & Seeman, T. E. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2990-0 · Cited by 8
Management of bone mineral density in HIV-infected patients
Negredo, E., Bonjoch, A., & Clotet, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1146690 · Cited by 9
Osteoporosis-related knowledge among Serbian postmenopausal women
Vujasinović-Stupar, N., Radojčić, L., Tadić, I., et al. (2016) · Vojnosanitetski pregled · doi:10.2298/vsp150716107v · Cited by 7
Pharmacological management of osteoporosis – when to treat and when to stop
Vannucci, L., & Brandi, M. L. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1203252 · Cited by 7
Delayed wound healing after tooth extraction and self-reported kyphosis in Japanese men and women
Taguchi, A., Kamimura, M., Nakamura, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep36309 · Cited by 7
Wiznia, D. H., Ndon, S. U., Kim, C.-Y., Zaki, T. D., & Leslie, M. P. (2016) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458516681635 · Cited by 7
OSTEOPOROSIS IN CHILDREN AND ITS RELEVANCE FOR PEDIATRIC SPORTS MEDICINE
Kljuchnikov, S. O., Kravchuk, D. A., & Ogannisyan, M. G. (2017) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2016-61-3-112-120 · Cited by 9
Martínez, P., Galve-Calvo, E., Arrazubi, V., et al. (2017) · Reumatología Clínica · doi:10.1016/j.reuma.2017.08.005 · Cited by 7
Sensory and nutritional evaluation of beverages developed using malted ragi (Eleusine coracana)
Bansal, M., & Kaur, N. (2018) · Journal of Applied and Natural Science · doi:10.31018/jans.v10i1.1618 · Cited by 7
Булавенко, О. В., Татарчук, Т. Ф., Konkov, D. G., & Furman, O. V. (2018) · Reproductive Endocrinology · doi:10.18370/2309-4117.2018.39.38-44 · Cited by 10
Reynolds, A. W., Liu, G., Kocis, P. T., Skowronski, J. N., LESLIE, D. L., & Fox, E. J. (2018) · Intern J Endocrinol Metab · doi:10.5812/ijem.12104 · Cited by 7
Boche, M., & Pokharkar, V. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0558-9 · Cited by 8
Doosti‐Irani, A., Ghafari, M., & Cheraghi, Z. (2018) · PubMed · Cited by 7
Muñoz, J. S., Kettenberger, U., Procter, P., & Pioletti, D. P. (2018) · Clinical Biomechanics · doi:10.1016/j.clinbiomech.2018.09.023 · Cited by 8
Assessing the Quality of Osteoporosis Care in Practice
Weng, W., Hess, B., Lynn, L. A., et al. (2015) · Journal of General Internal Medicine · doi:10.1007/s11606-015-3342-2 · Cited by 7
Okimoto, N., Uemura, Y., Yoshioka, T., Arita, S., Tsurukami, H., Otomo, H., Nishida, S., Ogawa, T., Hirao, K., Ikeda, S., et al. (2018) · Health Science Reports · doi:10.1002/hsr2.107 · Cited by 7
Tribst, M. F., Magalhães, L. R., Silva, R. A., Caetano, H. R. D. S., de Oliveira, W. G. A., Rufino, M. N., Keller, R., Sanches, O. D. C., Louzada, M. J. Q., & Bremer‐Neto, H. (2019) · Ciência Rural · doi:10.1590/0103-8478cr20180695 · Cited by 7
Fuzzell, L. N., Richards, M. J., Fraenkel, L., Stark, S. L., & Politi, M. C. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05008-4 · Cited by 8
Shim, J., Lin, T., Dashiell-Earp, C. N., Nechrebecki, M., & Leung, A. M. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0085-8 · Cited by 7
Lesnyak, O. M., Gladkova, E. N., Ershova, O. B., Skripnikova, I. A., Аношенкова, О. Н., Akhverdyan, Y., Belova, K. Y., Белоусова, И. Б., Bolshakova, E. V., Dreval', A. V., et al. (2019) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2019-626-635 · Cited by 7
Time to benefit and the long-term persistence of new users of oral bisphosphonates
Friesen, K. J., Bugden, S., & Falk, J. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01069-x · Cited by 9
Genetic Determinants and Pharmacogenetics of Osteoporosis and Osteoporotic Fracture
Hsu, Y., Xu, X., & Jeong, S. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_25 · Cited by 9
Association of asthma with osteopenia, osteoporosis, osteomalacia, and fractures
Shaheen, M. S., & Silverberg, J. I. (2020) · Allergy and Asthma Proceedings · doi:10.2500/aap.2020.41.190035 · Cited by 8
Significance of Fortification of Beneficial Natural Ingredients in Milk and Milk Products
Minj, J., & Dogra, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-2608-4_5 · Cited by 10
Johnson, T. C., Fox, E., & Hassanbein, S. (2021) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/21514593211002157 · Cited by 7
“Preventative Services Task Force, bone mineral density (BMD) testing should be performed by DXA for: 1) women age 65 and older and men age 70 and older, 2) postmenopausal women and men above age 50-69, based on risk factor profile, and 3) postmenopausal women and men age 50 and older who have had an adult age fracture…”
BackgroundMethodCorticosteroid use in chronic dermatologic disorders and osteoporosis
Lupsa, B. C., Insogna, K. L., Micheletti, R. G., & Caplan, A. S. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.07.014 · Cited by 8
Kim, J. H., Jeong, H. E., Baek, Y., Cho, S. W., Lim, H., & Shin, J. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01259-6 · Cited by 7
Cui, R., Xu, X., Wenxue, G., Zhaoliang, F., Hui, S., & Qu, S. (2022) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01291-6 · Cited by 7
“The osteoporosis diagnostic criteria [20] from the World Health Organization in men aged ≥ 50 years and postmenopausal women were based on the T score.”
MethodSerum Bioavailable Vitamin D Concentrations and Bone Mineral Density in Women After Obesity Surgery
Botella-Carretero, J. I., Lafuente, C., Montes‐Nieto, R., Balsa, J. A., Vega‐Piñero, B., García‐Moreno, F., Peromingo, R., Galindo, J., San‐Millán, J. L., & Escobar-Morreale, H. F. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2185-1 · Cited by 8
Chang, P.-Y., Saechao, F. S., Lee, J. S., Haskell, S. G., Frayne, S. M., & Lee, J. S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3655-y · Cited by 7
Griffith, J. F., & Genant, H. K. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00064-9 · Cited by 9
Sciamanna, C., Ballentine, N. H., Bopp, M., Brach, J. S., Chinchilli, V. M., Ciccolo, J. T., Conroy, M. B., Fisher, A., Fox, E. J., Greenspan, S. L., et al. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.09.006 · Cited by 9
Self-citationAntipsychotic use and fracture risk: An evaluation of incidence at a Veterans Affairs medical center
Weaver, J., Kawsky, J., & Corboy, A. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.01.006 · Cited by 7
Changes in Musculoskeletal System and Metabolism in Osteoporotic Rats Treated With Urocortin
Saul, D., Geisberg, L. K., Gehle, T., Hoffmann, D. B., Tezval, M., Sehmisch, S., & Komrakova, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00400 · Cited by 7
Exploration of Osteoporosis Knowledge and Perception among Young Women in Quetta, Pakistan
Tahir, N. U. H. M., & Naseem, Q. I. A. (2015) · Journal of Osteoporosis and Physical Activity · doi:10.4172/2329-9509.1000145 · Cited by 7
Diabetes, Bone Density, and Fractures
Shivaswamy, V. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s1-004 · Cited by 7
Kubo, H., Hirai, H., & MACHII, K. (1992) · PubMed · Cited by 7
Fractures in Kidney Transplant Recipients: A Comparative Study Between England and New York State.
Arnold, J. J., Mytton, J., Evison, F., et al. (2017) · Experimental and Clinical Transplantation · doi:10.6002/ect.2017.0016 · Cited by 7
Editorial: Response to the American College of Physicians Osteoporosis Guideline, 2017 Update
Caplan, L., Hansen, K. E., & Saag, K. G. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40305 · Cited by 7
Clinical Pharmacology of Bisphosphonates
Sinha, P. S., & Rosen, H. N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11259-0 · Cited by 8
Kirk, J. M., Rathbun, A. M., Gruber‐Baldini, A. L., Hochberg, M. C., Magaziner, J. S., Shardell, M. D., & Orwig, D. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07211-4 · Cited by 6
“The medications historically or currently prescribed as AOM for secondary fracture prevention include nitrogen-containing bisphosphonates (e.g., alendronate), calcitonin, and parathyroid hormone analogs (e.g., teriparatide), and monoclonal antibodies (e.g., denosumab) [11, 12].”
Ahmad, S., Tahir, N., Nauman, R., Gupta, A. K., Gewelber, C. L., Batra, K., & Izuora, K. E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195812 · Cited by 13
“OP is often referred to as a “silent disease” because it progresses without symptoms until a fragility fracture occurs as its first clinical presentation, making it imperative to understand and address the factors that contribute to its development [6].”
BackgroundBazi Bushen attenuates osteoporosis in SAMP6 mice by regulating PI3K ‐ AKT and apoptosis pathways
Xu, Z., Zhang, Z., Zhou, H., Lin, S., Gong, B., Li, Z., Zhao, S., Hou, Y., Peng, Y., & Bian, Y. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70161 · Cited by 7
Köhli, P., Hambrecht, J., Wang, S., Zhu, J., Chiapparelli, E. A., Schönnagel, L., Guven, A. E., Evangelisti, G., Kienzle, A., Shue, J., et al. (2024) · Spine · doi:10.1097/brs.0000000000005231 · Cited by 10
“24 As the risk for post-operative mechanical complications after spinal surgery due to osteoporosis 1,25 is higher than the risk of osteo-porotic major fractures, 11,26 a recent best practice guideline suggests screening of male patients > 65 years undergoing elective spinal reconstruction surgery.”
Periodontitis: Grade Modifiers Revisited
Saleh, O., Abdulmunim, A., Aboushakra, I., Shah, M. S., Hakam, A. E., Alsabeeha, N. H. M., & Atieh, M. A. (2025) · Oral Diseases · doi:10.1111/odi.15297 · Cited by 7
“The BMD results are often compared with healthy young adults of similar gender and ethnicity, and T-scores are calculated as the difference between the patient's BMD and the reference population's mean BMD divided by the reference population's standard deviation (SD) (Cosman et al. 2014).”
Chen, L., Tang, J., Zhang, L., Zheng, L., Wang, F., Guo, F., Han, Y., Song, X., Lv, W., Cao, W., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516013 · Cited by 6
Farshbaf‐Khalili, A., Malekmirzaei, E., Babaie, S., & Pakpour, V. (2025) · Scientific Reports · doi:10.1038/s41598-025-12755-4 · Cited by 6
“…Likert scale: 1: “Never”; 2: “Rarely”; 3: “Sometimes”; 4: “Often”; and 5: “Always” The possible total scores for the subscales are as follows: general health (45), screening (30), nutrition (25), memory (15), hot flashes and night sweats (15), sexuality (15), and social communication (20).”
InfluentialHejazi, K., Rahimi, G. R. M., & Hofmeister, M. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01594-5 · Cited by 8
“Although fragility fractures often occur later in life, targeting this earlier phase may have preventative implications by maximizing peak bone retention and minimizing later fracture risk [15].”
Wang, L., Mi, Y., Zhu, X., Liu, Z., Liu, J., Zhao, C., Zhao, S., Liang, H., Zhang, J., Gao, T., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03210-5 · Cited by 11
Cao, S., Li, X., Feng, T., Li, Y., Ding, H., Xie, L. Y., & Yang, Q. (2021) · Bioengineered · doi:10.1080/21655979.2021.2008697 · Cited by 7
“Osteoporosis is one of the public health problems in the elderly population and postmenopausal females, characterized by low bone mass and deteriorated bone structure in bone tissue [1].”
BackgroundBernatz, J. T., Winzenried, A. E., Hare, K. J., Mikula, A. L., Williams, S. K., Binkley, N., & Anderson, P. A. (2022) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-21-00253 · Cited by 25
Chan, L. N., Chen, L.-M., Goldman, M. E., Mak, J. S., Bauer, D. C., Boscardin, W. J., Schembri, M. E., Bae-Jump, V. L., Friedman, S. J., & Jacoby, V. L. (2023) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005236 · Cited by 8
Lin, S., Chen, W., Ku, C.-K., Chen, Y., Chen, C., & Chien, L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad449 · Cited by 6
CAREY, J. J., Erjiang, E., Wang, T., et al. (2023) · JBMR Plus · doi:10.1002/jbm4.10798 · Cited by 6
“(1,2,7,39,40) Because there is signi fi cant overlap between those who will and will not fracture, no single threshold can identify such people with certainty.”
Sim, M.-G., Teo, Y. N., Teo, Y. H., Syn, N. L. X., Li, T. Y., Yeo, L. L. L., Kong, W. K. F., Tan, B. Y., Yip, J., Wong, R. C.-C., et al. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.07.008 · Cited by 9
Song, L., Zhou, Y., Qu, L., Wang, D., Diao, X., Zhang, X., Zhai, Y., Zhang, Y., Yu, Y., & Zhou, K. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073243559231023065934 · Cited by 8
Yaman, A., Özdemir, O., Gök, Ş., Karahan, S., & Kutsal, Y. G. (2024) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2023.54036 · Cited by 6
Li, Z., Wu, X., Li, H., Bi, C., Zhang, C., Sun, Y., & Yan, Z. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05693-4 · Cited by 12
“Aligned with the insights of the International Osteoporosis Foundation, osteoporosis is aptly defined as a condition characterized by low bone mass and the progressive deterioration of bone micro-structure, culminating in heightened bone fragility and an elevated risk of fractures [21].”
Managing Micronutrient Deficiencies in High-Risk Patients: No Small Feat!
Steele, E. R., Liu, D., & Omer, E. M. (2024) · Current Nutrition Reports · doi:10.1007/s13668-024-00552-w · Cited by 6
Shaik, A., Larsen, K. S., Lane, N. E., Chen, Z., Su, K., Keyak, J. H., Tian, Q., Sha, Q., Shen, H., Deng, H., et al. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101805 · Cited by 10
“According to their criteria, bone density is considered normal when the T-score is (cid:0) 1 or greater, while osteopenia is characterized by T-scores ranging between (cid:0) 1 and (cid:0) 2.5, and osteoporosis is diagnosed when the T-score falls at (cid:0) 2.5 or below (Cosman et al., 2014).”
BackgroundInfluentialRisikofaktoren und Präventionsstrategien periprothetischer Femurfrakturen in der Hüftendoprothetik
Alimy, A., Soltys, P. J., Hubert, J., et al. (2024) · Die Orthopädie · doi:10.1007/s00132-024-04566-8 · Cited by 6
Aktuelle Osteoporoseprophylaxe und -therapie
Bartl, R., & Bärtl, C. (2015) · Der Internist · doi:10.1007/s00108-015-3791-z · Cited by 6
Wade, S. W., Satram‐Hoang, S., & Stolshek, B. S. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2762-x · Cited by 6
Rogers, T., Garrod, M. G., Peerson, J. M., Hillegonds, D. J., Buchholz, B. A., Demmer, E., Richardson, C., Gertz, E., & Loan, M. D. V. (2016) · Bone Reports · doi:10.1016/j.bonr.2016.05.001 · Cited by 6
Wang, C., Wang, J., & Luo, Y. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5787 · Cited by 6
Documento de consenso de osteoporosis del varón
Varsavsky, M., Muñoz, M. R., Rubio, V. Á., Becerra, A., Martín, A. G., Diaz‐Guerra, G. M., Moreno, P. R., Gimeno, E. J., & Muñoz‐Torres, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.12.005 · Cited by 8
Under-Recognition of Fractures as Osteoporosis Indicators
Lagari, V. S., Al-Yatama, F., Rodríguez, G., Berger, H. R., & Levis, S. (2019) · Geriatrics · doi:10.3390/geriatrics4010009 · Cited by 6
A case‐control study of the association between sialolithiasis and osteoporosis
Hung, S., Xirasagar, S., Cheng, Y., & Lin, H. (2019) · Clinical Otolaryngology · doi:10.1111/coa.13310 · Cited by 6
Namikawa, T., Yokota, K., Iwabu, J., Munekage, M., Uemura, S., Tsujii, S., Maeda, H., Kitagawa, H., Karashima, T., Kumon, M., et al. (2020) · JGH Open · doi:10.1002/jgh3.12347 · Cited by 6
Rodionova, S. S., Khakimov, U. R., Morozov, A. K., & Krivova, A. V. (2020) · Health Risk Analysis · doi:10.21668/health.risk/2020.2.14.eng · Cited by 6
“Frequently fractures not only give a clear signal the disease has already developed but also cause grave health disorders or even death [11].”
BackgroundLeslie, W. D., Edwards, B. J.-A., Al‐Azazi, S., Yan, L., Lix, L. M., Czaykowski, P. M., & Singh, H. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05596-6 · Cited by 7
Patients’ first-year adherence to different anti-osteoporotic therapy after hip fractures
Kim, S., Cho, Y. J., & Lee, D.-W. (2020) · Injury · doi:10.1016/j.injury.2020.11.041 · Cited by 7
Fritz, R., Edwards, L. R., & Jacob, R. (2021) · Southern Medical Journal · doi:10.14423/smj.0000000000001231 · Cited by 6
Efficacy of Pulsed Electromagnetic Fields on Experimental Osteopenia in Rodents: A Systematic Review
Wang, L., Xie, S., Zhu, S., Gao, C., & He, C. (2021) · Bioelectromagnetics · doi:10.1002/bem.22348 · Cited by 6
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.